Mayank Bansal, CFA
Mayank Bansal is a CFA Charterholder and heads the Equity Research team at Kapitales Research, with over 5 years of experience analysing global equity markets. He leads fundamental, data-driven research combining rigorous financial analysis with macro trends.
Medtech Firm Cites Short Interest After ASX Price Query Over Sharp Share Drop
Highlights
Introduction
On 2 November 2026, 4DMedical Limited (ASX: 4DX) replied to a price query from the Australian Securities Exchange (ASX). The query, dated 30 October 2026, followed a steep fall in the share price and a surge in trading volume. Price queries are a standard tool the exchange uses to check that the market has all the information it needs. Here is what was asked and how the company answered. 4DMedical Limited is currently trading at AU$2.150.
Why the ASX Stepped In
The exchange pointed out that shares moved from a high of AU$3.28 at the close of trade on 29 October 2026 to a low of AU$2.41 the next day, a fall of about 26%. It also noted a significant jump in the number of shares traded. The ASX put five questions to the company, covering whether any unannounced information could explain the moves, whether the company was complying with Listing Rule 3.1 and whether its answers were properly authorised. A reply was required by 9:30 AM AEDT on Monday 2 November 2026, with a warning that failing to respond could lead to a trading suspension.
How the Company Responded
4DMedical said it was not aware of any unannounced information that could explain the recent trading, so the follow-up questions about relying on Listing Rule 3.1A were marked not applicable. Asked for another explanation, it said that, to the best of its knowledge, an increase in short interest was responsible. It also confirmed that it was complying with the Listing Rules, particularly Rule 3.1. Company Secretary Hamish George signed the letter, which stated that the Chair and Chief Executive Officer approved the answers on behalf of the Board under the company’s Continuous Disclosure Policy.
What It Means for Investors
The reply gives shareholders a clear statement that the company sees no hidden news behind the fall. Short interest refers to shares sold by investors expecting the price to drop, so heavy activity can add pressure to a share price. The ASX usually releases this kind of correspondence to the market, which lets investors read the exchange for themselves.
Outro
The exchange of letters shows how the ASX tests whether the market is fully informed when a share price moves sharply. Investors should read the full correspondence and seek professional advice before making decisions.
Note: All data presented is based on information available at the time of writing.
Disclaimer for Kapitales Research
The materials provided by Kapitales Research, including articles, news, data, reports, opinions, images, charts, and videos ("Content"), are intended for personal, non-commercial use only. The primary goal of this Content is to educate and inform readers. This Content is not meant to offer financial advice, nor does it include any recommendation or opinion that should be relied upon for making financial decisions. Certain Content on this platform may be sponsored or unsponsored, but it does not serve as a solicitation or endorsement to buy, sell, or hold any securities, nor does it encourage any specific investment activities. Kapitales Research is not authorized to provide investment advice, and we strongly advise users to seek guidance from a qualified financial professional, such as a financial advisor or stockbroker, before making any investment choices. Kapitales Research disclaims all liability for any direct, indirect, incidental, or consequential damages arising from the use of the Content, which is provided without any warranties. The opinions expressed by contributors or guests are their own and do not necessarily reflect the views of Kapitales Research. Media such as images or music used on this platform are either owned by Kapitales Research, sourced through paid subscriptions, or believed to be in the public domain. We have made reasonable efforts to credit sources where appropriate. Kapitales Research does not claim ownership of any third-party media unless explicitly stated otherwise.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.Disclosure: The information mentioned above has been sourced from the company reports and a third-party database, i.e. Koyfin. Investors are advised to use strict stop-loss to protect their investments in case of any unfavorable/uncertain market events.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au